```html

Koch's Disease (Tuberculosis) – A Comprehensive Medical Guide

Overview

​Tuberculosis (TB), also known as **Koch’s disease** after the German physician Robert Koch who discovered the responsible bacterium Mycobacterium tuberculosis in 1882, is an infectious disease that most commonly attacks the lungs (pulmonary TB) but can affect almost any organ (extrapulmonary TB). It spreads through airborne droplets when a person with active pulmonary TB coughs, sneezes, speaks, or sings.

​According to the World Health Organization (WHO), an estimated 10.6 million people fell ill with TB worldwide in 2022, and about 1.4 million died from the disease, making TB the leading cause of death from a single infectious agent—ahead of HIV/AIDS.<sup>[1] WHO Global Tuberculosis Report 2023</sup> In high‑income countries the incidence is lower (< 5 cases per 100 000 people per year), whereas low‑ and middle‑income nations, especially in Southeast Asia and Sub‑Saharan Africa, account for > 85 % of cases.<sup>[2] CDC, 2024</sup>

Symptoms

Symptoms differ between latent infection (the bacteria are dormant) and active disease. The guide below focuses on **active TB**, the stage that requires treatment and is contagious.

Pulmonary (Lung) TB

• Persistent cough lasting ≥ 3 weeks, sometimes with blood‑tinged sputum.
• Chest pain or discomfort that may worsen with deep breathing.
• Hemoptysis (coughing up blood) – a red‑flag sign.
• Fever (usually low‑grade, 37.5–38.5 °C) that may be more pronounced in the evenings.
• Night sweats – soaking‑wet clothing and sheets.
• Unexplained weight loss (often > 5 % of body weight).
• Fatigue or malaise** – a generalized feeling of being unwell.

Extrapulmonary TB

• Lymph node TB – painless, firm swelling in the neck, armpits, or groin.
• TB meningitis – severe headache, neck stiffness, altered mental status, fever; occurs mainly in children and immunocompromised adults.
• Spinal (Pott’s) disease – back pain, spinal deformity, neurological deficits.
• Genitourinary TB – frequent urination, blood in urine, pelvic pain.
• Pericardial TB – chest pain, shortness of breath, low‑grade fever.
• Disseminated (miliary) TB – fever, weight loss, organ‑specific symptoms; “miliary” refers to the millet‑seed pattern seen on imaging.

Causes and Risk Factors

TB is caused by infection with Mycobacterium tuberculosis, a slow‑growing, aerobic, acid‑fast bacillus. Transmission occurs when airborne particles (< 5 µm) containing viable bacteria are inhaled.

Key Risk Factors

• Close contact with an infectious case – household members, coworkers, or people in congregate settings (prisons, shelters, homeless shelters).
• Immunosuppression – HIV infection (people with HIV are 20‑30 times more likely to develop active TB), organ transplantation, cancer chemotherapy, or use of biologic agents (TNF‑α inhibitors).
• Malnutrition – low body mass index (< 18.5 kg/m²) impairs cellular immunity.
• Substance use – smoking, alcohol dependence, and illicit drug use increase susceptibility.
• Diabetes mellitus – approximately three‑fold higher risk of active TB.
• Advanced age – immune senescence in people > 65 years.
• Silicosis or other lung diseases – silica dust damages alveolar macrophages.
• Living in or traveling to high‑burden regions – India, China, Indonesia, the Philippines, Pakistan, Nigeria, South Africa.

Diagnosis

Accurate diagnosis combines clinical assessment, radiology, and microbiological testing.

Step‑by‑Step Diagnostic Pathway

1. Medical History & Physical Exam – Evaluate symptoms, exposure history, risk factors.
2. Chest Radiograph (CXR) – Typical findings include upper‑lobe infiltrates, cavitations, or nodular lesions.
3. Sputum Examination
   • Acid‑fast bacilli (AFB) smear microscopy – Rapid (within hours) but less sensitive.
   • Nucleic Acid Amplification Tests (NAAT) – e.g., GeneXpert MTB/RIF detects DNA and rifampin resistance in < 2 hours.
   • Culture – Gold standard; grows on solid (Löwenstein–Jensen) or liquid (MGIT) media; results in 2‑8 weeks.
4. Interferon‑Gamma Release Assays (IGRAs) – Blood tests (Quantiferon‑TB Gold, T‑Spot) to detect latent infection; not useful for active disease alone.
5. Tuberculin Skin Test (TST) – Mantoux test; may be false‑negative in immunocompromised patients.
6. Additional Imaging – CT scan for complex pulmonary disease or extrapulmonary sites; MRI for TB meningitis or spinal involvement.
7. Biopsy / Histopathology – Required for many extrapulmonary forms; granulomatous inflammation with caseating necrosis is classic.

Treatment Options

Effective therapy requires a combination of antibiotics taken for a prolonged period to eradicate the slow‑growing bacilli and prevent resistance.

First‑Line Anti‑TB Regimen (Drug‑Sensitive TB)

Drug	Typical Dose (adult)	Duration
Isoniazid (INH)	5 mg/kg (max 300 mg) daily	6 months (continuation phase)
Rifampin (RIF)	10 mg/kg (max 600 mg) daily	6 months
Pyrazinamide (PZA)	15–30 mg/kg daily	2 months (intensive phase)
Ethambutol (EMB)	15–25 mg/kg daily	2 months

This 2‑month intensive phase (HRZE) followed by a 4‑month continuation phase (HR) is the standard 6‑month regimen recommended by WHO and CDC.<sup>[3] CDC TB Treatment Guidelines 2023</sup>

Drug‑Resistant TB (MDR/XDR)

• MDR‑TB – resistance to at least INH and RIF; treated with second‑line drugs (fluoroquinolones, bedaquiline, linezolid, clofazimine) for 18–24 months.
• XDR‑TB – MDR plus resistance to any fluoroquinolone and at least one second‑line injectable; requires individualized regimens often including newer agents (delamanid, pretomanid).

Directly Observed Therapy (DOT) is strongly recommended for all patients to ensure adherence.

Adjunctive Therapies & Lifestyle Measures

• Vitamin D supplementation – May enhance immune response; dose per physician discretion.
• Smoking cessation – Reduces treatment failure and relapse.
• Nutrition support – High‑protein diet, daily caloric intake 1.5 × basal metabolic rate.
• Management of comorbidities – Tight glycemic control in diabetics, antiretroviral therapy for HIV.
• Surgical intervention – Reserved for complications (e.g., extensive cavitary disease, spinal instability, drug‑resistant meningitis).

Living with Koch's Disease (Tuberculosis)

Adhering to treatment and caring for overall health are essential for cure and to prevent transmission.

Practical Daily‑Management Tips

• Take medication exactly as prescribed – Use a pillbox or mobile reminder.
• Complete the full course – Even if symptoms improve after a few weeks.
• Attend all follow‑up appointments – Sputum checks at 2 months and at the end of therapy.
• Infection control at home
  • Keep windows open for ventilation.
  • Cover mouth/nose with a surgical mask when coughing.
  • Use a separate bedroom if possible until sputum is negative.
• Nutrition – Aim for 1,800–2,200 kcal/day, include iron‑rich foods, and stay hydrated.
• Exercise – Light activity (walking, yoga) improves stamina; avoid heavy exertion until weight stabilizes.
• Monitor side effects – Liver toxicity (INH, RIF, PZA), visual changes (EMB), joint pain (PZA). Report any new symptoms promptly.
• Address mental health – Anxiety and stigma are common; seek counseling or support groups.

Prevention

Preventing infection and progression from latent to active disease are the twin pillars of TB control.

Primary Prevention

• BCG vaccination – Gives variable protection against severe childhood TB; recommended in high‑burden countries.
• Infection‑control measures – Negative‑pressure rooms in hospitals, UV‑GI lamps, proper use of N95 respirators for healthcare workers.
• Screening of high‑risk groups – Annual TST/IGRA for people with HIV, close contacts of active cases, and workers in congregate settings.

Secondary Prevention (Treating Latent TB Infection – LTBI)

Individuals with a positive IGRA/TST but no active disease should receive preventive therapy, e.g.,:

• Isoniazid for 6–9 months (INH ± Rifapentine weekly for 12 weeks – “3HP” regimen).
• Rifampin for 4 months.

Treatment of LTBI reduces the risk of progression to active disease by up to 90 %.<sup>[4] WHO Guidelines on LTBI 2022</sup>

Complications

If left untreated, TB can lead to serious, sometimes fatal complications.

• Pulmonary complications – Massive hemoptysis, bronchiectasis, fibrotic scarring, respiratory failure.
• TB meningitis – Hydrocephalus, permanent neurological deficits, death.
• Pott’s disease (spinal TB) – Vertebral collapse, spinal cord compression, paralysis.
• Disseminated (miliary) TB – Multi‑organ failure; high mortality.
• Drug‑induced hepatotoxicity – Acute liver failure if not recognized early.
• Secondary infections – Superimposed bacterial pneumonia.

When to Seek Emergency Care

References

1. World Health Organization. Global Tuberculosis Report 2023. Geneva: WHO; 2023. https://www.who.int/publications/i/item/9789241565719
2. Centers for Disease Control and Prevention. TB Surveillance, USA 2023. Atlanta, GA: CDC; 2024. https://www.cdc.gov/tb/data.htm
3. Centers for Disease Control and Prevention. Treatment of Tuberculosis. Updated 2023. https://www.cdc.gov/tb/topic/treatment/default.htm
4. World Health Organization. Guidelines for Management of Latent Tuberculosis Infection. 2022. https://www.who.int/publications/i/item/9789241550310
5. Mayo Clinic. Tuberculosis (TB). 2024. https://www.mayoclinic.org/diseases-conditions/tuberculosis/symptoms-causes/syc-20351250
6. Cleveland Clinic. Tuberculosis (TB): Diagnosis and Treatment. 2024. https://my.clevelandclinic.org/health/diseases/13136-tuberculosis

```